Clinical trial NCT01026558: A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients
Official title: Open-Label, Single Dose, Parallel Group Pharmacokinetic Study of Ceftobiprole in Morbidly Obese and Non-Obese Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Obesity
Staphylococcal Skin Infections
Streptococcal Infections
Keywords: Obesity, Ceftobiprole
Skin Infections
Staphylococcal Skin Infections
Bacterial Skin Infections
Streptococcal Infection
Lead sponsor: Basilea Pharmaceutica
Sponsor class: INDUSTRY
Collaborators: name: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First posted: 2009-12-04
Enrollment: 25
Sex: ALL
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The primary objective of this study is to compare the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of ceftobiprole in morbidly obese patients and non-obese patients. The secondary objectives are to assess the pharmacodynamics (the study of the action or effects a drug has on the body) and to assess safety and tolerability of ceftobiprole in order to support dosing recommendations in the morbidly obese population.

Detailed description: This is an open-label (all people involved know the identity of the intervention), parallel-group, Phase 1 study in morbidly obese and non-obese men and women. A total of 25 patients (12 morbidly obese and 13 non-obese) patients will be enrolled in the study. Morbidly obese and nonobese patients are matched individually 1:1 by age (±10 years), sex, and renal function (as defined by creatinine levels in the urine). There are 4 phases in the clinical study: the pretreatment (screening/baseline) phase of up to 21 days; the 2-day open-label treatment phase when each patients receives a single 2-hour intravenous (directly into the vein) infusion of ceftobiprole 500 mg followed by multiple (up to 15) blood and urine samples drawn over the 24 hours following study drug administration; and the follow-up phase of approximately 1 week after the last blood sample when each patient will be monitored by telephone for development of new adverse events and assessment of ongoing adverse events. Each patient receives a single 2-hour infusion (directly into the vein) of ceftobiprole 500 mg

Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI) =or \> 40 kg/m2 or normal BMI between 18-30
* Blood pressure 90-140 mm
* Non-smoker

Exclusion Criteria:

* History of medically significant illness
* Uncontrolled hypertension
* Uncontrolled high blood cholesterol and triglycerides

Primary outcomes:
measure: The pharmacokinetics of ceftobiprole in morbidly obese patients and non-obese patients
timeFrame: up to 30 days (up to 21 days screening plus 2 days open-label treatment phase plus 1-week follow-up).
Secondary outcomes:
measure: To assess the pharmacodynamics of ceftobiprole in morbidly obese patients and non-obese patients.
timeFrame: Up to 30 days (up to 21 days screening plus 2 days open label treatment phase plus 1-week follow-up)
measure: To assess safety and tolerability of ceftobiprole in order to support dosing recommendations in the morbidly obese population.
timeFrame: Throughout the study from Day -1 through the post-study follow up
Other outcomes:
Locations:
Study officials:
affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
name: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
role: STUDY_DIRECTOR
References: